PIN15 COST-EFFECTIVENESS OF AUGMENTIN ES® FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND  by Kawalec, P et al.
old cohort (13.6 vs. 11.3 years). The incremental costs/LYG and
death avoided were €406 and €4730, respectively. Although the
model was sensitive to variables like proven MRSA percentage
and costs accrued by patients who die, varying these parameters
by 25% the overall conclusions remained the same. CONCLU-
SION: According to this model, Linezolid is cost-effective versus
vancomycin for MRSA suspected-nosocomial pneumonia in
Spain, with and additional cost/LYG and death avoided below
the acceptable threshold.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs Augmentin® conventional twice-daily
regimen (45/6.4 mg/kg/day in two divided doses) in acute otitis
media treatment in Poland from the public payer (NHF) and
payer (NHF + patient) perspective. METHODS: Systematic
review according to Cochrane Collaboration guidelines and clini-
cal effectiveness analysis according to Polish HTA Guidelines
were performed. Medline (Pubmed) Cochrane and EMBASE
were searched (August 2006). Only RCTs with high credibility
assessment (based on Jadad scale) were included in the systematic
review. Overall costs of treatment were taken into account,
including cost of pharmacotherapy, drug administration, second-
line therapy, complications of otitis media and adverse events.
Sensitivity analysis was performed according to a range of acqui-
sition costs of Augmentin ES® and Augmentin® (20%). All
calculations were performed for 2006 (€1 = PLN3.8). RESULTS:
Randomized head-to-head clinical trial of Augmentin ES® vs
conventional Augmentin® was found and signiﬁcant difference
in clinical cure rate between two drugs was revealed: 84.1% vs
78.8%, respectively; no signiﬁcant differences in safety proﬁle
were found. Cost analysis revealed that savings per patient when
Augmentin ES® is used in place of conventional Augmentin®
were: PLN28.27 (€7.4) (public payer) and PLN27.9 (€7.3)
(payer). Results of clinical and cost analysis proved that conven-
tional Augmentin® therapy is dominated by Augmentin ES®.
The results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
Augmentin® were: PLN533.4 (€140.3) (public payer perspec-
tive) and PLN526.4) (€138.5) (payer perspective). CONCLU-
SION: Augmentin ES® compared with conventional therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs azithromycin (10 mg/kg, day 1; 5 mg/kg/d,
days 2–5) in acute otitis media treatment in Poland from the
public payer (NHF) and payer (NHF + patient) perspective.
METHODS: Systematic review according to Cochrane Collabo-
ration guidelines and clinical effectiveness analysis according to
Polish HTA Guidelines were performed. Medline (Pubmed)
Cochrane and EMBASE were searched (August 2006). Only
RCTs with high credibility assessment (based on Jadad scale)
were included in the systematic review. Overall costs of treatment
were taken into account, including cost of pharmacotherapy,
drug administration, second-line therapy, complications of otitis
media and adverse events. Sensitivity analysis was performed
according to a range of acquisition costs of Augmentin ES® and
azithromycin (+/-20%). All calculations were performed for
2006 (€1 = PLN3.8). RESULTS: Randomized head-to-head clini-
cal trial of Augmentin ES® vs azithromycin was found and
signiﬁcant difference in clinical cure rate between two drugs was
revealed: 90.5% vs 80.9%, respectively; no signiﬁcant differences
in safety proﬁle were found. Cost analysis revealed that savings
per patient when Augmentin ES® is used in place of azithromy-
cin were: PLN49 (€12.9) (public payer) and PLN38.3 PLN
(€10.1) (payer). Results of clinical and cost analysis proved that
azithromycin therapy is dominated by Augmentin ES®. The
results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
azithromycin were: PLN510.5 (€134.3) (from public payer per-
spective) and PLN399.2 (€105) (payer perspective). CONCLU-
SION: Augmentin ES® compared with azithromyycin therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: HPV epidemiology and screening practices vary
considerably between countries and speciﬁc analyses are required
to estimate the impact of prophylactic cervical cancer vaccination.
This study adapted a health economic model to Italy to predict the
clinical and economic impact. METHODS: A Markov model
based upon the natural history of HPV and cervical cancer was
developed to simulate transitions between health states (normal,
HPV, Cervical Intraepithelial Neoplasia stages 1 to 3, Cervical
Cancer (CC) stages 1 to 4, and death) in the presence of speciﬁc
screening programs. Italian data was used to for costs, and
screening and treatment practices, and published clinical data was
used to estimate efﬁcacy against oncogenic HPV types 16, 18, 31,
45. The model was calibrated to Italian epidemiological data
including age-speciﬁc HPV prevalence, prevalence of CIN lesions,
CC incidence and mortality. The cost-effectiveness of vaccination
against HPV for cohorts of different ages was assessed using the
calibrated model. RESULTS: With 100% vaccine coverage, in a
12 year old cohort of females there is estimated to be a 68%
reduction in the prevalence of high-grade precancerous lesions due
to oncogenic HPV, and a 78% and 79% reduction in cervical
cancer cases and deaths, respectively. Vaccination would also
produce substantial reductions in these outcomes for the 18 and
25 year old cohorts, and in the number of screening tests and
treatments required. With 3% discount rates on costs and out-
comes, vaccination is cost effective in cohorts of 12, 18, and 25
year oldswith estimated cost perQALYs of €30,624, €31,078, and
€31,116 respectively. CONCLUSION: The model was success-
fully adapted to represent Italian epidemiological data, screening
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